This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Aptose Biosciences’s 8K filing here.
About Aptose Biosciences
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
Featured Stories
- Five stocks we like better than Aptose Biosciences
- Most Volatile Stocks, What Investors Need to Know
- Is Marvell Technology Chipping Away at NVIDIA’s Market Lead?
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Quantum Computing Inc. is a Leader in the Industry, For How Long?
- NYSE Stocks Give Investors a Variety of Quality Options
- Consumer Discretionary Stocks Soar but Is a Pullback Looming?
